Thank you, everyone. Frank. And good morning,
look II programs we the HPV-associated we clinical initiation cancers. Phase our three PDSXXXX of As to advanced addressing ahead, committed remain
be the COVID-XX initiated. timelines exact are pandemic, However, will when due provide trials these for to unable to we
Let me three you quickly highlight for these studies.
with of the first and study of and in II recurrent trial combination The the Phase head efficacy evaluate will KEYTRUDA neck is HPVXX treatment safety that a or patients line positive in anti-PDX with PDSXXXX first metastatic cancer. therapy Merck's
vast the treatment. second of been majority have Historically, combination line for or designated studies third
disease. recurrent ability So, of metastatic very with setting the this care first for standard we in are the about cancer excited the to address therapy line
initiate We study presents plan this do collaborate believe this several so. when to and advantages to safe opportunities. and to We're distinct honored with Merck
known inhibitor, Our EMD the immunotherapies PDSXXXX combination both in that and clinical study This have ongoing second two clinical Cancer Merck planned well-recognized in is immune studies MXXXX, being by preclinical bifunctional at with II highly This National run Institute. checkpoint combination generated by of shown Europe. also strong Phase this result Institute. promising Cancer will trial clinical cytokine, triple study owned with – is National evaluate a KgaA as a NHS-ILXX, in an the promise data Serono,
study standard II advanced care radiation leading research the in run Phase cancer. study cervical locally planned by with patients being third This institute. is trial of The will combination chemo clinical and PDSXXXX Phase II cancer a of
safely We with to when two can determine studies available. look these institutions we and forward when are begin both working closely update an providing to
and with we announced need. NCI lung tumors to of breast, work which PDSXXXX, treatment of of protein research the and PDSXXXX recently a ovarian, degree high the our potential to cooperative is with colorectal addition in agreement in overexpression the MUC-X cancers, expansion for of the unmet our initiate with associated In the development of studies
Institute Cancer cells Laboratory immune to recognize can T The the PDSXXXX these which that protein Immunology by Versamune with express and program recognized Biology novel sequences highly arm used by combined and the with system attack from Versamune at killer National and cancers our MUC-X with MUC-X. of Tumor to are and be better our short developed
multiple disease poor and is progress be MUC-X prognosis. present protein The and types, it's with been resistance shown associated tumor drug highly to in
to agreement expanded combination NCI, human agents. preclinical and our we with Under studies with therapeutic the conduct PDSXXXX potentially collaborating clinical other are in of studies
discussed to to pertaining specifically our for robust immediate we've some disease our programs. highlight of in immuno-oncology, like I'd priorities activities our Now infectious recent that pipeline, next
collaboration develop, and one The disease to infectious planned application in our by its with Versamune in recent is versatility tuberculosis. Farmacore always of we've evidenced as
unfold, the to of has stage. development taken the pandemic vaccines As continues COVID-XX center
demonstrated Our immune immunity. has and the greater arms presents to both of long-term provide breadth therapeutic potential ability a our of system, platform which protective Versamune the to activate preventative the
space We currently in forward disease rapidly. infectious have moving development that two are programs the
Our COVID-XX. potentially advancing leading is and provide against infectious a broad disease designed long-term program, vaccine PDSXXXX to as protection
as Versamune disease, the T cells, antibodies, immunity both close against in T cause associated attacking response a A SARS-CoV-X is importantly, current protective memory of relative when strong with of cells. T viral COVID-XX as well paired enhanced virus infectious induces the with cell The neutralizing killer the antigen, pandemic. has the that and very SARS, been specifically platform,
the antibodies, Versamune's both provide virus mutations. ability enhanced with T may immunity and neutralizing significantly attacking against its virus potential cells, to induce together the
cells will preclinical induce killer specific will SARS-CoV-X the This COVID-XX initial of response. preclinical month, T These ability to studies Versamune's studies antibodies and SARS-CoV-X. initial These be induction as to characterize and used both our studies to well evaluate for confirmation immune neutralizing vaccine of we as candidates. anti helper provide initiated an
outer only of provide shell being the virus. which Further, our with means to regions center includes not be stable of the but potential improved of part less the also the system more of likely This recognize protection more is against to virus, virus. possible virus. trained mutations has the mutate, Versamune administered the should to help that the This immune protein SARS-CoV-X the variable proprietary
advance to are COVID-XX We our to clinical discussions path currently forward with on updates we program. continue agencies governmental near and most both the in additional advance look this to as We providing in active vaccine NGOs the into future accelerated rapidly trials.
is of on development Our a tuberculosis the antigens, second Versamune. disease Farmacore vaccine Biotechnology TB proprietary for a program collaboration novel with infectious based with of therapeutic combined part PDSXXXX, Farmacore
Tuberculosis and tuberculosis as also is mycobacterium manifests significantly other that disease vaccine organs. caused tuberculosis. symptoms To no can there therapeutic by primarily available affect an is infectious respiratory for date,
promising and development PDSXXXX, specific In will of safety Under cell induction collaboration the formulated we to highly a demonstrated continue will preliminary evaluations, candidate evaluate conduct product product. of our this in and vivo. Versamune-based Farmacore with the product, Farmacore, T efficacy studies TB
support this in whole, this collaboration to hopeful diseases. through early well still approach validate Versamune preclinical are platform our we While studies, as to a as as generated our infectious is the that will continue program data
through and With additional both value programs on look well in diseases. as potential of as protection, a to platform infectious we providing We updates tremendous programs, treatment variety treating these of make continue believe to progress as holds Versamune our this robust very cancers providing and we pipeline of forward that XXXX.
to hand Bedu-Addo. CEO, Frank? our Frank I'll Dr. back now
